Free Trial
NASDAQ:ATAI

atai Life Sciences (ATAI) Stock Price, News & Analysis

atai Life Sciences logo
$2.78 +0.03 (+0.91%)
Closing price 03:59 PM Eastern
Extended Trading
$2.76 -0.01 (-0.36%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About atai Life Sciences Stock (NASDAQ:ATAI)

Key Stats

Today's Range
$2.62
$2.80
50-Day Range
$1.38
$2.78
52-Week Range
$1.03
$2.96
Volume
4.12 million shs
Average Volume
2.01 million shs
Market Capitalization
$555.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

atai Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

ATAI MarketRank™: 

atai Life Sciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 1132nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    atai Life Sciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about atai Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of atai Life Sciences is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of atai Life Sciences is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    atai Life Sciences has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about atai Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.00% of the float of atai Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    atai Life Sciences has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in atai Life Sciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    atai Life Sciences does not currently pay a dividend.

  • Dividend Growth

    atai Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.00% of the float of atai Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    atai Life Sciences has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in atai Life Sciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    atai Life Sciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for atai Life Sciences this week, compared to 2 articles on an average week.
  • Search Interest

    16 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, atai Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 28.41% of the stock of atai Life Sciences is held by institutions.

  • Read more about atai Life Sciences' insider trading history.
Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

ATAI Stock Analysis - Frequently Asked Questions

atai Life Sciences' stock was trading at $1.33 on January 1st, 2025. Since then, ATAI shares have increased by 108.6% and is now trading at $2.7750.

atai Life Sciences N.V. (NASDAQ:ATAI) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business earned $1.56 million during the quarter.

atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/14/2025
Today
7/03/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATAI
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+224.3%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$149.27 million
Pretax Margin
-7,999.62%

Debt

Sales & Book Value

Annual Sales
$310 thousand
Price / Cash Flow
N/A
Book Value
$0.69 per share
Price / Book
4.02

Miscellaneous

Free Float
146,647,000
Market Cap
$555.94 million
Optionable
Optionable
Beta
1.44
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ATAI) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners